See today's BioWorld Asia
To read the full story, subscribe or sign in.

FDA grants breakthrough therapy designation to Abbisko’s CSF-1R inhibitor, pimicotinib

Jan. 31, 2023
By Tamra Sami
The U.S. FDA granted breakthrough therapy designation to Abbisko Therapeutics Co. Ltd.’s pimicotinib for patients with tenosynovial giant cell tumors who are not able to have surgery.
BioWorld Asia Regulatory Cancer China FDA